Skip to main content
main-content

09-08-2017 | SGLT2 inhibitors | Podcast | Audio

SGLT2 inhibitors: The story so far

Editorial board member John Wilding discusses the lessons for healthcare professionals from the SGLT2 inhibitor cardiovascular outcome trials about the benefits and drawbacks of the medication class (14:07).

More on this topic

image credits